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Abstract
Background: We developed a modified-release hydrocortisone, Chronocort, to replace the cortisol rhythm in patients 
with congenital adrenal hyperplasia. Food, alcohol and pH affect drug absorption, and it is important to assess their 
impact when replicating a physiological rhythm. 
Subjects and methods: In vitro dissolution to study impact of alcohol and pH on Chronocort. A phase 1, three-period, 
cross over study in 18 volunteers to assess the impact of food on Chronocort and to compare bioavailability to 
immediate-release hydrocortisone.
Results: In vitro dissolution of Chronocort was not affected by gastrointestinal pH up to 6.0 nor by an alcohol 
content up to 20% v/v. Food delayed and reduced the rate of absorption of Chronocort as reflected by a longer Tmax 
(fed vs fasted: 6.75 h vs 4.5 h, P = 0005) and lower Cmax (549.49 nmol/L vs 708.46 nmol/L, ratio 77% with CI 71–85). 
Cortisol exposure was similar in fed and fasted state: Geo LSmean ratio (CI) AUC0t for fed/fasted was 108.33%  
(102.30–114.72%). Cortisol exposure was higher for Chronocort compared to immediate-release hydrocortisone: 
Geo LSmean ratios (CI) 118.83% (111.58–126.54%); however, derived free cortisol showed cortisol exposure CIs were 
within 80.0–125.0%: Geo LSmean ratio (CI) for AUC0t 112.73% (105.33–120.65%).
Conclusions: Gastric pH ≤6.0 and alcohol do not affect hydrocortisone release from Chronocort. Food delays 
Chronocort absorption, but cortisol exposure is similar in the fasted and fed state and exposure as assessed by free 
cortisol is similar between Chronocort and immediate-release hydrocortisone. 
Introduction
Cortisol has a distinct circadian rhythm with low levels at 
night, rising in the early hours of the morning, peaking 
on waking and declining over the day to low levels in the 
evening (1). Current immediate-release hydrocortisone 
therapy cannot replace this circadian rhythm; patients 
take twice or thrice daily hydrocortisone, and despite 
this, cortisol levels are suboptimal in many patients with 
adrenal insufficiency (2). This is a particular problem in 
patients with adrenal insufficiency due to congenital 
adrenal hyperplasia who have poor health outcomes 
(3). To address this, a number of technologies have 
been developed including hydrocortisone infusions (4), 
and modified-release formulations of hydrocortisone; 
Plenadren a once-daily modified-release hydrocortisone 
(5), and Chronocort a delayed and sustained absorption 
modified-release hydrocortisone that replicates the 
overnight profile of cortisol (6). 
Food influences the absorption of immediate-
release hydrocortisone; delaying and increasing the 
variability of the Cmax, prolonging the absorption 
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half-life and decreasing oral clearance (7). Cortisone when 
taken with food shows an increased cortisol Cmax and 
AUC; however, this was not considered to be clinically 
significant (8). In adrenal insufficiency, cortisol levels are 
low on waking at a time when they should be highest 
so most clinicians recommend taking hydrocortisone on 
waking although many patients will take food shortly 
afterward (7). The impact of food on modified-release 
formulations of hydrocortisone is likely to depend on the 
type of formulation developed. Plenadren is a dual release 
tablet with an immediate release coating and extended 
release core (5). Plenadren is recommended to be taken 
before breakfast and in the fasted state has approximately 
20% lower bioavailability compared to immediate 
release hydrocortisone based on the AUC of cortisol (9). 
Plenadren taken with food shows similar changes to 
those seen with immediate-release hydrocortisone with 
a delayed Cmax and an approximately 30% increase in 
AUC (10). Chronocort is a multi-particulate formulation 
that has a pH-dependent delayed release coating that 
allows for delayed release and sustained absorption (6). 
This manuscript reports the in vitro impact of alcohol and 
pH on the release of hydrocortisone from Chronocort, 
the in vivo impact of food on the pharmacokinetics of 
Chronocort and compares bioavailability to immediate-
release hydrocortisone. 
Materials, methods and subjects
In vitro dissolution studies of pH and alcohol
An in vitro dissolution methodology using rotating basket 
USP apparatus 1 (Sotax AT7 smart system) was developed 
to best represent the expected dissolution conditions 
in vivo. Briefly, dissolution vessels were filled with 700 mL 
of USP-simulated gastric fluid (pH 1.2) and pre-warmed to 
37 ± 0.5°C. In separate vessels, sufficient buffer to adjust 
the pH of the media was pre-warmed. Chronocort (5 or 
20 mg hydrocortisone) capsules were added to each basket 
and once the media was at the required temperature, they 
were lowered into the media, with the rotating speed set 
to 100 rpm. At 30-min intervals, 1–2 mL of sample was 
collected for analysis. The samples were vialled neat for 
analysis. The amount of hydrocortisone dissolved in 
the media was determined by HPLC analysis (Agilent 
1100/1200 system) using reverse-phase chromatography 
with UV detection at 254 nm. The impact of gastric 
conditions and alcohol concentration on Chronocort 
was evaluated by dissolution testing under three different 
study conditions: 
1. pH 1.2 for 0.5 h, pH-change to 4.5 for 2.5 h, pH-change 
to 7.2 for 1.5 h.
2. pH 4.5 for 3 h, pH-change to 7.2 for 1.5 h.
3. pH 1.2 for 2 h, pH-change to 6.0 for 1 h, pH-change 
to 7.2 for 1.5 h. All media were mixed with alcohol 
(ethanol) to produce a concentration of 5, 10, 20 or 
40% v/v alcohol. 
Calculation of dissolution profile comparison by f2 
test was carried out according to the following formula:
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where Rt and Tt are the cumulative percentage dissolved 
at each of the selected number (n) of time points of the 
reference dissolution profile and test dissolution profile 
respectively. Two dissolution profiles are considered 
similar when the similarity factor (f2) value is >50.
In vivo pharmacokinetic studies fasted, fed and 
relative bioavailability
Human studies were undertaken at Simbec Research Ltd 
(Merthyr Tydfil, UK). Eighteen healthy male volunteers, 
mean age of 34 years (s.d. 9.3) and mean BMI of 24.91 kg/m2 
(s.d. 1.8) participated in this open label, randomized, 
single-dose, three-period, cross over, single center, phase 
1 study (www.clinicaltrials.gov trial NCT02408068). The 
primary objectives of the study were to compare the 
pharmacokinetics of Chronocort under fed and fasted 
conditions at a single dose of 20 mg and to evaluate the 
relative bioavailability of Chronocort and immediate-
release hydrocortisone. The three periods were Chronocort 
20 mg in fed state (30 min after the start of a high-fat, 
high-calorie diet), Chronocort 20 mg in fasted state (10-h 
overnight fast) and hydrocortisone 20 mg in fasted state 
(10-h overnight fast). A minimal washout period of 
7 days was ensured between each study period. Seventeen 
subjects completed the study, one subject was withdrawn 
due to treatment emergent adverse events (TEAE) after 
oral dexamethasone administration.
In study periods 1 and 2 (Chronocort 20 mg in fed 
state and fasted state) dexamethasone-suppressed subjects 
(1 mg dexamethasone administered at 22:00 h on Day 1, 
and at ~06:00, ~12:00, ~18:00 and ~22:00 h on Day  1) 
were admitted to the clinical unit on the previous day 
and remained until completion of all procedures (i.e. 24 h 
after dose). During the fed study subjects were required to 
fast for at least 10 h overnight and then receive a high-fat, 
high-calorie breakfast approximately 30 min before dosing 
in the morning of Day 1. During fasted study period, 
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subjects were required to fast from 20:00 h on previous 
day until 4 h after dose on Day 1. Each dose of the study 
medication was administered at 08:00 h and 30 min after 
starting breakfast during the fed study period. A sample 
for basal blood serum cortisol was drawn pre dose (0 min–
08:00 h) and further pharmacokinetic samples were drawn 
up to 24 h (every 30 min for 8 h, every 60 min up to 16 h 
and every 120 min up to 24 h). 
In study period 3 (hydrocortisone fasted), 
dexamethasone-suppressed subjects (1 mg dexamethasone 
administered at 22:00 h on Day 1, and at ~06:00, ~12:00 
and ~18:00 h on Day 1) were admitted to the clinical unit 
on the previous day and remained until completion of 
all procedures (i.e. 12 h after dose). Subjects fasted from 
20:00 h on previous day until 4 h after dose on Day  1. 
Blood for serum cortisol were collected before dose 
(0 min–08:00 h) and up to 12 h (15 min, 30 min, 45 min, 
1 h, 1.25 h, 1.5 h, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h 
and 12 h). 
Assays
Cortisol was measured by LC-MS/MS using an Applied 
Biosystems MDS Sciex API365 mass spectrometer with 
Perkin Elmer Series 200 LC system with an electrospray 
source in negative ionization mode. Cortisol was measured 
in serum with the lower limit of quantitation (LLOQ) 
and upper limit of quantitation (ULOQ) of 0.50 and 
250 ng/mL respectively. Reproducibility (relative standard 
deviation) RSD% was equal to <15% at the LLOQ QC 
(cortisol 0.50 ng/mL) and <10% at the low, medium and 
high QC level (cortisol 8, 30 and 200 ng/mL).
Pharmacokinetics (PK)
It was calculated from serum cortisol and derived free 
cortisol by non-compartmental analysis, using baseline-
adjusted concentrations. All calculations were done using 
WinNonlin Professional, version 5.3.
Food effect and comparative bioavailability
After logarithmic transformation, Cmax, AUC0−t and AUC0−inf 
values were subjected to a mixed effects analysis of variance 
(ANOVA) including fixed effects for sequence, period 
and treatment and a random effect for subject nested 
within sequence. Point estimates and 90% confidence 
intervals (CI) were constructed for the contrasts between 
treatments using the residual mean square error obtained 
from the ANOVA. The point and interval estimates were 
then backtransformed to give estimates of the ratios 
of the geometric least squares means (LSmean) and 
corresponding 90% CI. In addition, estimated geometric 
means were produced for each treatment. An assessment 
of Tmax was performed using the Wilcoxon matched-
pairs test. In addition, a 95% non-parametric CI was 
constructed for the median difference in Tmax. Derived 
free cortisol was calculated for each sampling time point 
using the equation: y = 3E−20x5 −1E−15x4 + 1E−11x3 − 
6E−08x2 + 0.0002x + 0.0306 (x = serum cortisol, y = derived 
free cortisol) (11). Serum cortisol and derived free cortisol 
were baseline adjusted using the 0-h sample for each subject, 
per treatment and values less than zero were set to zero. 
For calculation of derived PK parameters, concentrations 
below the lower limit of quantification were also assigned 
a value of zero. 
Ethics
All human studies were approved by the South East 
Wales Research Ethics Committee, and all participants 
gave written informed consent. The study protocol was 
authorised by the Medicines and Healthcare products 
Regulatory Agency (MHRA).
Results
In vitro impact of gastric pH
There was no significant drug release observed in pH 1.2 
and 4.5 dissolution media prior to the third and final 
pH change to pH 7.2 media. The dissolution profiles of 
Chronocort 5 and 20 mg modified-release capsules were 
comparable across the range of physiological pH conditions 
studied. All dissolution profiles were comparable to the 
standard Chronocort dissolution profile (Fig.  1) when 
assessed using the f2 similarity test, with all values >50 
(f2: 80–95). Chronocort 5 and 20 mg modified-release 
capsules continue to meet the compendial acceptance 
criteria for delayed-release dosage forms, demonstrating 
the integrity of the functional enteric coating was 
maintained in different acidic pH conditions and release 
of hydrocortisone was delayed until exposure to pH 7.2 
media (Fig. 1).
In vitro impact of alcohol
From 5 to 20% v/v of alcohol (ethanol) in the dissolution 
media, the obtained release profiles for Chronocort 20 mg 
modified-release capsules were all comparable to the 
standard Chronocort dissolution profile when assessed 
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using the f2 similarity test, with all values >50 (f2: 68–70). 
The Chronocort modified-release formulation retains its 
gastro-resistant, enteric properties in up to 20% v/v alcohol 
over 3 h until media pH is changed to 7.2, triggering 
dissolution of the enteric coating and drug release (Fig. 2). 
A high concentration 40% v/v alcohol in the media led 
to a change in the dissolution profile, resulting in a value 
for the f2 similarity test outside of the acceptance criteria. 
However, only a moderate increase in drug release was 
observed over the dissolution experiment, with 27% 
drug release after 30 min, 57% after 1 h, 81% after 1.5 h 
and 95% after 2 h (n = 12 samples). At the high 40% v/v 
alcohol concentration, the rate of drug release increases, 
albeit without any observed dose dumping (Fig. 2).
In vivo PK analysis
18 subjects who had concentrationtime profiles for 2 
treatments and adequately suppressed pre-dose cortisol 
(<60 nmol/L) were included in the PK population. 
Hydrocortisone profiles of 4 subjects were excluded from 
the PK analysis of immediate-release hydrocortisone; 
two subjects did not suppress on one occasion each, one 
subject did not receive hydrocortisone tablets due to an 
adverse event after dexamethasone, one did not have a 
baseline sample performed. 
Food effect on Chronocort
The rate of hydrocortisone absorption from Chronocort 
was reduced and delayed when administered in fed 
state (after a high-fat, high-calorie breakfast) when 
compared to the fasted state, as reflected by a lower Cmax 
(549.49 nmol/L vs 708.46 nmol/L geometric LSmean ratio 
77.56% with 90% C.I. 70.89–84.86%) and longer Tmax 
(6.75 h vs 4.5 h, P = 0.0005) (Fig. 3 and Table 1). Geometric 
LSmean of AUC0−t and AUC0−inf were similar during fed 
(3229.26 and 2980.85 h*nmol/L) and fasted (3273.59 and 
2985.31 h*nmol/L) study periods and the fed/fasted ratio 
CIs were within 80.0–125.0% indicating that the overall 
exposure to hydrocortisone was similar during fed and 
fasted periods. The t1/2 was the same for fed and fasted 
Chronocort administration at 1.38 h, and CL/F was similar 
at 16.70 and 18.48 L/h, respectively. 
Figure 1
Chronocort 5 and 20 mg capsules in vitro dissolution (n = 6), 
mean hydrocortisone release in three different pH media 
conditions: (i) pH 1.2 (2 h), pH 6.0 (1 h), pH 7.2 (1.5 h);  
(ii) pH 1.2 (0.5 h), pH 4.5 (2.5 h), pH 7.2 (1.5 h); (iii) pH 4.5 (3 h),  
pH 7.2 (1.5 h). (s.d. error is within each point).
Figure 2
Chronocort 20 mg capsules in vitro dissolution in alcoholic 
media (n = 12), mean hydrocortisone release in 5, 10, 20 or 
40% v/v alcohol mixed in pH 1.2 (2 h), pH 6.0 (1 h) and  
pH 7.2 (1.5 h) test conditions (s.d. error is within each point).
Figure 3
Mean (s.e.m.) cortisol concentration after immediate-release 
hydrocortisone fasted and Chronocort fasted and fed in 
healthy volunteers.
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Comparative bioavailability of Chronocort vs 
hydrocortisone tablets—fasted
For serum cortisol, the geometric LSmean and test/reference 
ratio indicate that Chronocort is more bioavailable than 
the hydrocortisone tablets (Table  2). Overall exposure 
(AUC0−t and AUC0−inf) is approximately 19% higher for 
Chronocort, as reflected by geometric LSmean ratios of 
approximately 119%. When compared to hydrocortisone 
tablets, the rate of absorption is also reduced and delayed 
after administration of Chronocort as reflected by a 
lower Cmax (708.46 nmol/L vs 850.82 nmol/L, Geometric 
LSmean Ratio 74.75% with 90% CI of 64.08–87.19%) 
and longer Tmax (4.5 h vs 0.88 h, P = 0.0014). The t1/2 was 
similar for Chronocort and hydrocortisone tablets at 1.38 
and 1.40 h respectively. The CL/F appears to be higher for 
the hydrocortisone tablets when compared to Chronocort 
at 22.24 and 18.48 L/h respectively. Analysis of derived 
free cortisol suggests Chronocort exposure was within 
80.0–125.0% CIs based on AUC0−t and AUC0−inf (Table 3).
Discussion
Chronocort modified-release in vitro dissolution was 
neither affected by prolonged exposure to gastric 
dissolution media up to pH 6.0 nor by an alcohol 
content up to 20% v/v, demonstrating that the polymer 
system used to provide the delayed release functionality 
affords a robust enteric performance without resulting in 
premature coat dissolution or affecting the downstream 
release of hydrocortisone. Taking Chronocort with food 
delayed and reduced the cortisol Cmax but did not affect 
the overall cortisol exposure. Chronocort showed greater 
comparative bioavailability when compared to immediate-
release hydrocortisone although this was within 80–125% 
CIs when adjusted for protein binding.
Gastric pH in healthy individuals may vary between 
pH 1.0 and 2.5 preprandial and then increases as food is 
ingested to reach a pH of ≤5.0 before returning to normal 
gastric pH values; after gastric emptying, medication 
passes through the small intestine where pH values in 
the distal ileum are reported to vary between pH 6.5 
and 8.0 (12, 13). Chronocort was designed to release 
hydrocortisone in the last third of the small bowel to 
allow for delayed and sustained absorption (6). The multi-
particulate formulation approach was selected to provide 
more predictable, reproducible gastrointestinal transit 
over single-unit oral dosage forms (14). To achieve its 
release profile, the multi-particulate beads of Chronocort 
are coated with the polymer EUDRAGIT (S100/L100) 
designed to dissolve at pH ≥6.8. Our data presented here 
demonstrate that the enteric coat does not dissolve at pH 
values ≤6.0 and drug release only occurs above the enteric 
coat pH 6.8 trigger point. This is of importance suggesting 
that there should not be a problem taking Chronocort 
with concomitant medication that raises gastric pH, 
such as proton pump inhibitors where the gastric pH can 
typically rise above 4.0 but not > than pH 6.0 (15, 16). 
Table 1 Summary of the statistical analysis of food effect on Chronocort PK for serum cortisol (baseline adjusted)  
(PK population).
PK parameter
IMPs: 20 mg hydrocortisone  
Chronocort fed vs Chronocort fasted**Chronocort (fed) (n = 18)* Chronocort (fasted) (n = 18)*
Cmax (nmol/L) 549.49 708.46 77.56 (70.89–84.86)
AUC0−t (h*nmol/L) 3229.26 2980.85 108.33 (102.30–114.72)
AUC0−inf (h*nmol/L) 3273.59 2985.31 109.66 (103.19–116.53)
Tmax (h) 6.75
† 4.5† 2.25 (1.25–3.75) (0.0005)††
*Geometric LS mean; **Geometric LS mean (90%CI); †Median; ††Median difference (95% CI) (P value). 
Table 2 Summary of the statistical analysis of bioavailability between chronocort and hydrocortisone tablets (fasted) for serum 
cortisol (baseline adjusted) (PK population).
PK parameter
IMPs: 20 mg hydrocortisone Chronocort fasted vs hydrocortisone  
tablets fasted**Chronocort (fasted) (n = 18)* Hydrocortisone tablets (fasted) (n = 14)*
Cmax (nmol/L) 708.46 850.82 83.27 (75.58–91.74)
AUC0−t (h*nmol/L) 2980.85 2508.52 118.83 (111.58–126.54)
AUC0−inf (h*nmol/L) 2985.31 2510.82 118.90 (111.58–126.69)
Tmax (h) 4.5
† 0.88† 3.50 (2.25–4.38) (0.0014)††
*Geometric LS mean; **Geometric LS mean (90%CI); †Median; ††Median difference (95% CI) (P value). 
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Alcohol can influence drug absorption from modified-
release dosage forms and potentially on the dissolution 
of the enteric coating of drugs (17). Concomitant 
consumption of alcoholic beverages with such products 
may induce dose dumping (18). We examined the 
effect of alcohol on the dissolution of Chronocort as 
it is designed to be taken last thing at night to provide 
the overnight rise in cortisol, and in many cultures, it 
is common to have alcohol in the evening. From 5 to 
20% v/v of alcohol, there was no effect of alcohol on 
hydrocortisone release confirming that Chronocort 
meets the EMA regulatory guidelines for alcohol testing 
of modified-release dosage forms (18). At a high alcohol 
concentration of 40% v/v recommended in the FDA 
guideline for testing (19), there was a change in the 
Chronocort dissolution profile observed, with a moderate 
increase in drug release over the 2 h but no significant 
alcohol-induced dose dumping. The conclusion from 
this study, is that dissolution of Chronocort modified-
release capsules are not perturbed by alcohol under 
typical consumption levels and shows no dose dumping. 
The strongest alcoholic spirits generally available for 
consumption are ca. 40% v/v alcohol which on ingestion 
would be very rapidly diluted to <20% v/v in the 
stomach. It has been calculated that to achieve a 40% v/v 
alcohol concentration in the stomach would require the 
intake into an empty stomach of 240 mL of an alcoholic 
beverage with 56% v/v alcohol content, based on 100 mL 
gastric fluid (20). Furthermore, hydrocortisone has a wide 
therapeutic index and long established safety profile, 
lowering the risk profile for Chronocort modified-
release capsules. For example, for some indications, 
i.e. asthma and COPD, doses up to 500 mg are used. 
Therefore, the concomitant consumption of alcoholic 
beverages presents no risk for Chronocort dose dumping.
Food is known to slow the absorption of many drugs 
as it slows gastric emptying and gut transit (14). We found 
that a high-fat, high-calorie meal delayed absorption of 
Chronocort but did not alter the overall cortisol exposure. 
For immediate-release hydrocortisone, the evidence shows 
that food delays the Cmax and increases exposure (7), and 
the same thing was true for the dual-release formulation 
of hydrocortisone Plenadren (10). The median time of 
Tmax for Chronocort given with food was 6.75 h and when 
fasted was 4.5 h. We have previously published data that 
shows when Chronocort 20 mg was given at 23:00 h at 
night a median Tmax of 6 h was achieved, similar to that 
when Chronocort 20 mg was taken in the morning with 
food. It is likely that a night-time dose has a delayed 
Tmax despite being without food due to increased gastric 
residence and slower gut motility during sleep (21). It is 
likely in clinical practice that patients will take Chronocort 
in the morning close to food, and this may give a delayed 
Tmax but will not increase exposure to cortisol.
Comparative bioavailability showed that Chronocort 
taken in fasted state gave greater cortisol exposure than 
immediate-release hydrocortisone, but when adjusted for 
protein binding, they gave similar cortisol exposure. This 
would be predicted as serum cortisol is highly protein 
bound and binding to plasma proteins is non-linear with 
higher plasma concentrations having a greater unbound 
fraction than lower concentrations (11), and the unbound 
fraction having more rapid clearance (22). When taking 
20 mg immediate-release hydrocortisone, the Cmax exceeds 
the binding capacity of cortisol-binding protein at a 
concentration of ~550 nmol/L, the free cortisol is more 
quickly cleared than the bound fraction and therefore 
the cortisol AUC for total cortisol is lower than it would 
be if it had not exceeded the binding capacity (11). In 
contrast, Chronocort gives a Cmax that is comparable 
to healthy subjects, and there is not such a great free 
portion although with its sustained absorption, the free 
cortisol exposure over time is similar to immediate release 
hydrocortisone. Thus, Chronocort, designed with a robust 
enteric coat, is unaffected by normal physiological pH 
and alcohol conditions encountered in normal daily life 
whilst providing cortisol replacement to levels which are 
similar to those found in healthy individuals.
Table 3 Summary of the statistical analysis of bioavailability between chronocort and hydrocortisone tablets (fasted) for derived 
free cortisol (baseline adjusted) (PK population).
PK parameter
IMPs: 20 mg hydrocortisone Chronocort fasted vs hydrocortisone  
tablets fasted**Chronocort (fasted) (n = 18)* Hydrocortisone tablets (fasted) (n = 14)*
Cmax (nmol/L) 106.06 141.89 74.75 (64.08–87.19)
AUC0−t (h*nmol/L) 326.87 289.96 112.73 (105.33–120.65)
AUC0−inf (h*nmol/L) 327.03 290.36 112.63 (105.39–120.36)
Tmax (h) 4.5
† 0.88† 3.50 (2.25–4.38) (0.0014)††
*Geometric LS mean; **Geometric LS mean (90%CI); †Median; ††Median difference (95% CI) (P value). 
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